n(6)-methoxyadenine profile

N(6)-methoxyadenine is a synthetic nucleoside analog that has been studied for its potential therapeutic applications. It is a structural analog of adenine, a purine base that is a fundamental component of DNA and RNA. The methoxy group at the N6 position of adenine alters its chemical and biological properties, making it a promising candidate for various research areas.'

ID Source	ID
PubMed CID	101511
CHEMBL ID	237173
SCHEMBL ID	5699092
MeSH ID	M0198178

Synonym
n6-methoxyadenine
nsc-529542
17124-24-2
nsc529542
CHEMBL237173
n-methoxy-7h-purin-6-amine
nsc 529542
1h-purin-6-amine, n-methoxy-
n(6)-methoxyadenine
SCHEMBL5699092
DTXSID70169037
n-methoxy-9h-purin-6-amine
o-methyl-n-(9h-purin-6-yl)hydroxylamine

Bioassays (7)

Assay ID	Title	Year	Journal	Article
AID300108	Selectivity index, ratio of CC50 for human KB cells to IC50 for Plasmodium falciparum VS1	2007	Bioorganic & medicinal chemistry, Aug-15, Volume: 15, Issue:16	Anti-malarial activity of N6-modified purine analogues.
AID300105	Cytotoxicity against human KB cells	2007	Bioorganic & medicinal chemistry, Aug-15, Volume: 15, Issue:16	Anti-malarial activity of N6-modified purine analogues.
AID300102	Antimalarial activity against drug-sensitive Plasmodium falciparum 3D7 after 24 hrs	2007	Bioorganic & medicinal chemistry, Aug-15, Volume: 15, Issue:16	Anti-malarial activity of N6-modified purine analogues.
AID300103	Antimalarial activity against chloroquine,pyrimethamine-resistant Plasmodium falciparum K1 after 24 hrs	2007	Bioorganic & medicinal chemistry, Aug-15, Volume: 15, Issue:16	Anti-malarial activity of N6-modified purine analogues.
AID300106	Selectivity index, ratio of CC50 for human KB cells to IC50 for Plasmodium falciparum 3D7	2007	Bioorganic & medicinal chemistry, Aug-15, Volume: 15, Issue:16	Anti-malarial activity of N6-modified purine analogues.
AID300107	Selectivity index, ratio of CC50 for human KB cells to IC50 for Plasmodium falciparum K1	2007	Bioorganic & medicinal chemistry, Aug-15, Volume: 15, Issue:16	Anti-malarial activity of N6-modified purine analogues.
AID300104	Antimalarial activity against chloroquine, pyrimethamine and cycloguanil-resistant Plasmodium falciparum VS1 after 24 hrs	2007	Bioorganic & medicinal chemistry, Aug-15, Volume: 15, Issue:16	Anti-malarial activity of N6-modified purine analogues.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	4 (25.00)	18.2507
2000's	1 (6.25)	29.6817
2010's	4 (25.00)	24.3611
2020's	7 (43.75)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (6.25%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	15 (93.75%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
adenine [no description available]	4.01	13	6-aminopurines; purine nucleobase	Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
cytosine [no description available]	7	1	aminopyrimidine; pyrimidine nucleobase; pyrimidone	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
thymine [no description available]	2	1	pyrimidine nucleobase; pyrimidone	Escherichia coli metabolite; human metabolite; mouse metabolite
chloroquine Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.	2.03	1	aminoquinoline; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; antirheumatic drug; autophagy inhibitor; dermatologic drug
dyphylline Dyphylline: A THEOPHYLLINE derivative with broncho- and vasodilator properties. It is used in the treatment of asthma, cardiac dyspnea, and bronchitis.. dyphylline : An oxopurine that is theophylline bearing a 2,3-dihydroxypropyl group at the 7 position. It has broncho- and vasodilator properties, and is used in the treatment of asthma, cardiac dyspnea, and bronchitis. It is also an ingredient in preparations that have been promoted for coughs.	2.05	1	oxopurine; propane-1,2-diols	bronchodilator agent; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; muscle relaxant; vasodilator agent
pyrimethamine Maloprim: contains above 2 cpds	2.03	1	aminopyrimidine; monochlorobenzenes	antimalarial; antiprotozoal drug; EC 1.5.1.3 (dihydrofolate reductase) inhibitor
podophyllotoxin Podophyllum: A genus of poisonous American herbs, family BERBERIDACEAE. The roots yield PODOPHYLLOTOXIN and other pharmacologically important agents. The plant was formerly used as a cholagogue and cathartic. It is different from the European mandrake, MANDRAGORA.	2.03	1	furonaphthodioxole; lignan; organic heterotetracyclic compound	antimitotic; antineoplastic agent; keratolytic drug; microtubule-destabilising agent; plant metabolite; tubulin modulator
6-hydroxyadenosine [no description available]	2.03	1
6-n-hydroxylaminopurine N(6)-hydroxyadenine : A member of the class of 6-aminopurinnes that is adenine in which one of the exocyclic amino hydrogens is replaced by a hydroxy group.	2.03	1	6-aminopurines; hydroxylamines; nucleobase analogue	mutagen; teratogenic agent
adenosine quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit	2.31	1	adenosines; purines D-ribonucleoside	analgesic; anti-arrhythmia drug; fundamental metabolite; human metabolite; vasodilator agent
2-amino-n(6)-hydroxyadenine 2-amino-N(6)-hydroxyadenine: mutagen & bacterial growth inhibitor; structure in first source. 2-amino-6-hydroxyaminopurine : A 2,6-diaminopurine that is the N(6)-hydroxy derivative of 2,6-diamino-3H-purine.	2.03	1	2,6-diaminopurines; hydroxylamines; nucleobase analogue	mutagen; teratogenic agent
n(6)-methoxyadenosine [no description available]	2.03	1
n(6)-ribosyladenine N(6)-ribosyladenine: N(6) analog of adenosine; N(9) compound is adenosine	2.31	1
thiourea Thiourea: A photographic fixative used also in the manufacture of resins. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance may reasonably be anticipated to be a carcinogen (Merck Index, 9th ed). Many of its derivatives are ANTITHYROID AGENTS and/or FREE RADICAL SCAVENGERS.. thiourea : The simplest member of the thiourea class, consisting of urea with the oxygen atom substituted by sulfur.	2.11	1	one-carbon compound; thioureas; ureas	antioxidant; chromophore
1-aminoadenosine 1-aminoadenosine: structure	2.03	1

Condition	Relationship Strength	Studies
Diathesis [description not available]	2.31	1
Diabetic Glomerulosclerosis [description not available]	2.31	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.69	2
Diabetic Nephropathies KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.	2.31	1
Carcinoma, Non-Small Cell Lung [description not available]	2.31	1
Carcinoma, Epidermoid [description not available]	2.31	1
Cancer of Lung [description not available]	2.31	1
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	2.31	1
Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)	2.31	1
Lung Neoplasms Tumors or cancer of the LUNG.	2.31	1
Disease A definite pathologic process with a characteristic set of signs and symptoms. It may affect the whole body or any of its parts, and its etiology, pathology, and prognosis may be known or unknown.	3.52	1
Colorectal Cancer [description not available]	2.6	1
Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.	2.6	1
Hepatitis B Virus Infection [description not available]	2.25	1
Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted [description not available]	2.25	1
Hepatitis B INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.	2.25	1
Hepatitis C INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown.	2.25	1
Metastase [description not available]	2.25	1
Cancer of Pancreas [description not available]	2.25	1
Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.	2.25	1
Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).	2.25	1
Glial Cell Tumors [description not available]	2.31	1
Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)	2.31	1

n(6)-methoxyadenine

Cross-References

Synonyms (13)

Bioassays (7)

Research

Studies (16)

Market Indicators

Research Demand Index: 12.17

Study Types

n(6)-methoxyadenine

Cross-References

Synonyms (13)

Bioassays (7)

Research

Studies (16)

Market Indicators

Research Demand Index: 12.17

Study Types

Related Drugs (15)

Related Conditions (23)